Medacta Group SA Logo

Medacta Group SA

0A05.L

(0.0)
Stock Price

123,60 CHF

8.41% ROA

17.4% ROE

54.33x PER

Market Cap.

2.654.589.185,07 CHF

43.88% DER

0.41% Yield

10.35% NPM

Medacta Group SA Stock Analysis

Medacta Group SA Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Medacta Group SA Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Medacta Group SA Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Medacta Group SA Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Hold

Medacta Group SA Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Medacta Group SA Revenue
Year Revenue Growth
2016 234.784.123
2017 286.025.179 17.91%
2018 306.963.419 6.82%
2019 337.148.775 8.95%
2020 327.142.917 -3.06%
2021 377.054.233 13.24%
2022 432.764.353 12.87%
2023 498.371.336 13.16%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Medacta Group SA Research and Development Expenses
Year Research and Development Expenses Growth
2016 3.333.372
2017 4.063.312 17.96%
2018 4.428.623 8.25%
2019 8.293.506 46.6%
2020 7.385.514 -12.29%
2021 11.739.658 37.09%
2022 16.061.273 26.91%
2023 18.732.312 14.26%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Medacta Group SA General and Administrative Expenses
Year General and Administrative Expenses Growth
2016 27.087.136
2017 34.127.851 20.63%
2018 37.845.422 9.82%
2019 53.492.626 29.25%
2020 48.896.452 -9.4%
2021 51.742.341 5.5%
2022 60.016.672 13.79%
2023 66.354.188 9.55%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Medacta Group SA EBITDA
Year EBITDA Growth
2016 72.342.762
2017 83.819.266 13.69%
2018 95.392.758 12.13%
2019 72.176.623 -32.17%
2020 88.634.823 18.57%
2021 101.566.838 12.73%
2022 105.890.751 4.08%
2023 139.505.920 24.1%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Medacta Group SA Gross Profit
Year Gross Profit Growth
2016 176.369.714
2017 213.456.006 17.37%
2018 229.684.892 7.07%
2019 242.799.695 5.4%
2020 231.716.319 -4.78%
2021 271.267.514 14.58%
2022 302.212.919 10.24%
2023 343.522.108 12.03%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Medacta Group SA Net Profit
Year Net Profit Growth
2016 42.035.866
2017 39.155.558 -7.36%
2018 51.518.643 24%
2019 12.871.704 -300.25%
2020 40.113.649 67.91%
2021 53.497.164 25.02%
2022 45.787.946 -16.84%
2023 56.925.524 19.57%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Medacta Group SA Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2016 1.051
2017 979 -7.36%
2018 3 -48800%
2019 1 0%
2020 2 100%
2021 3 0%
2022 2 0%
2023 3 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Medacta Group SA Free Cashflow
Year Free Cashflow Growth
2016 37.613.520
2017 24.852.137 -51.35%
2018 23.933.485 -3.84%
2019 1.260.144 -1799.27%
2020 34.939.788 96.39%
2021 7.860.359 -344.51%
2022 10.248.801 23.3%
2023 20.998 -48708.46%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Medacta Group SA Operating Cashflow
Year Operating Cashflow Growth
2016 60.357.625
2017 60.302.084 -0.09%
2018 74.776.518 19.36%
2019 46.275.832 -61.59%
2020 64.448.318 28.2%
2021 56.134.589 -14.81%
2022 72.777.182 22.87%
2023 18.295.746 -297.78%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Medacta Group SA Capital Expenditure
Year Capital Expenditure Growth
2016 22.744.105
2017 35.449.947 35.84%
2018 50.843.033 30.28%
2019 45.015.688 -12.95%
2020 29.508.530 -52.55%
2021 48.274.230 38.87%
2022 62.528.381 22.8%
2023 18.274.748 -242.16%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Medacta Group SA Equity
Year Equity Growth
2016 157.420.937
2017 118.848.387 -32.46%
2018 100.294.309 -18.5%
2019 133.757.616 25.02%
2020 178.140.248 24.91%
2021 235.080.791 24.22%
2022 271.916.978 13.55%
2023 290.645.805 6.44%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Medacta Group SA Assets
Year Assets Growth
2016 289.051.644
2017 350.466.559 17.52%
2018 411.667.210 14.87%
2019 447.795.068 8.07%
2020 477.949.517 6.31%
2021 508.032.519 5.92%
2022 578.661.269 12.21%
2023 629.579.568 8.09%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Medacta Group SA Liabilities
Year Liabilities Growth
2016 131.630.707
2017 231.618.171 43.17%
2018 311.372.901 25.61%
2019 314.037.451 0.85%
2020 299.809.268 -4.75%
2021 272.951.728 -9.84%
2022 306.744.291 11.02%
2023 338.933.762 9.5%

Medacta Group SA Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
23.65
Net Income per Share
2.45
Price to Earning Ratio
54.33x
Price To Sales Ratio
5.62x
POCF Ratio
33.87
PFCF Ratio
192.86
Price to Book Ratio
9.14
EV to Sales
5.56
EV Over EBITDA
22.24
EV to Operating CashFlow
33.52
EV to FreeCashFlow
190.9
Earnings Yield
0.02
FreeCashFlow Yield
0.01
Market Cap
2,65 Bil.
Enterprise Value
2,63 Bil.
Graham Number
28.32
Graham NetNet
-7.79

Income Statement Metrics

Net Income per Share
2.45
Income Quality
1.6
ROE
0.17
Return On Assets
0.08
Return On Capital Employed
0.15
Net Income per EBT
0.82
EBT Per Ebit
0.77
Ebit per Revenue
0.16
Effective Tax Rate
0.18

Margins

Sales, General, & Administrative to Revenue
0.13
Research & Developement to Revenue
0.04
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.69
Operating Profit Margin
0.16
Pretax Profit Margin
0.13
Net Profit Margin
0.1

Dividends

Dividend Yield
0
Dividend Yield %
0.41
Payout Ratio
0.21
Dividend Per Share
0.54

Operating Metrics

Operating Cashflow per Share
3.93
Free CashFlow per Share
0.69
Capex to Operating CashFlow
-0.82
Capex to Revenue
-0.14
Capex to Depreciation
-1.4
Return on Invested Capital
0.15
Return on Tangible Assets
0.08
Days Sales Outstanding
67.42
Days Payables Outstanding
99.75
Days of Inventory on Hand
456.75
Receivables Turnover
5.41
Payables Turnover
3.66
Inventory Turnover
0.8
Capex per Share
-3.24

Balance Sheet

Cash per Share
1,35
Book Value per Share
14,56
Tangible Book Value per Share
12.12
Shareholders Equity per Share
14.56
Interest Debt per Share
6.39
Debt to Equity
0.44
Debt to Assets
0.2
Net Debt to EBITDA
-0.23
Current Ratio
2.57
Tangible Asset Value
0,24 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
0.44
Working Capital
0,19 Bil.
Intangibles to Total Assets
0.08
Average Receivables
0,09 Bil.
Average Payables
0,04 Bil.
Average Inventory
183584528.5
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Medacta Group SA Dividends
Year Dividends Growth
2023 1

Medacta Group SA Profile

About Medacta Group SA

Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Europe, North America, the Asia-Pacific, and internationally. It offers personalized kinematic models and 3D planning tools for use in hip, knee, shoulder, sports medicine, and spine procedures. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.

CEO
Dr. Francesco Siccardi
Employee
1.662
Address
Strada Regina, 34
Castel San Pietro, 6874

Medacta Group SA Executives & BODs

Medacta Group SA Executives & BODs
# Name Age
1 Dr. Alberto Siccardi
Founder & Non Executive Chairman
70
2 Dr. Francesco Siccardi
Chief Executive Officer
70
3 Mr. Corrado Farsetta
Chief Financial Officer
70
4 Gianluca Olgiati
Senior Director of Global Marketing
70
5 Mr. Alessandro Siccardi
Chief Supply Chain Officer
70

Medacta Group SA Competitors